Inhaler Choices in Chronic Bronchitis

First-Line Treatment Options

For patients with low symptom burden and low exacerbation risk, the American Thoracic Society recommends starting with a bronchodilator to reduce breathlessness, and continuing treatment if symptomatic benefit is noted 1
For patients with high symptom burden and low exacerbation risk, initial therapy should be a long-acting bronchodilator, and for persistent breathlessness on monotherapy, use two bronchodilators (LABA/LAMA) 1, 2

For Group A patients, if inadequate response to initial bronchodilator, try alternative class of bronchodilator 2
For Group B patients, initial therapy should be a long-acting bronchodilator, and for severe breathlessness, initial therapy with two bronchodilators may be considered 1
For Group C patients, start with a LAMA as it is superior to LABA for exacerbation prevention, and consider LABA/LAMA combination or LABA/ICS combination if exacerbations persist 1, 2
For Group D patients, initiate LABA/LAMA combination as first choice, and consider escalation to LABA/LAMA/ICS triple therapy or switch to LABA/ICS if exacerbations persist 1, 2, 3

For patients with severe airflow obstruction or frequent exacerbations, consider adding an inhaled corticosteroid (ICS) with a LABA, and if patients on LABA/LAMA/ICS still have exacerbations, consider adding roflumilast or a macrolide 2, 3

Long-term monotherapy with ICSs is not recommended for chronic bronchitis, and Group D patients are at higher risk for pneumonia when receiving ICS treatment 1
ICS should be reserved for patients with a history of exacerbations despite appropriate treatment with long-acting bronchodilators 1

The American Thoracic Society recommends ipratropium bromide with a grade A recommendation for improving cough in stable patients with chronic bronchitis, as it reduces cough frequency, cough severity, and volume of sputum expectorated 4, 5, 6
The standard dosing is ipratropium bromide 36 μg (2 inhalations) four times daily 5
Short-acting β-agonists should be used to control bronchospasm and relieve dyspnea; in some patients, they may also reduce chronic cough (Grade A recommendation) 4, 5

The American College of Chest Physicians recommends antibiotics for acute exacerbations of chronic bronchitis, particularly for patients with severe exacerbations and those with more severe airflow obstruction at baseline (Grade A recommendation) 4
During acute exacerbations, both short-acting β-agonists and anticholinergic bronchodilators should be administered, with the addition of the other agent at maximal dose if prompt response is not observed 5, 6

For patients with inadequate response to ipratropium bromide after 2 weeks, consider adding a short-acting β-agonist for additional bronchodilation and potential cough relief 5, 6
For patients with severe airflow obstruction or frequent exacerbations, consider adding an inhaled corticosteroid with a long-acting β-agonist 5, 6

Long-term prophylactic therapy with antibiotics is not recommended for stable patients with chronic bronchitis due to concerns about antibiotic resistance and potential side effects (Grade I recommendation) 4

Ipratropium bromide should be offered to patients with stable chronic bronchitis to improve cough; it reduces cough frequency, cough severity, and sputum volume. Grade A recommendation (good level of evidence, substantial net benefit) from the American College of Chest Physicians. 7
The American College of Chest Physicians specifically recommends ipratropium bromide with Grade A strength for improving cough in stable chronic bronchitis, reflecting robust evidence of benefit. 8
Ipratropium bromide significantly decreases the volume of sputum expectorated in chronic bronchitis patients. Grade A. 7

During acute exacerbations of chronic bronchitis, both short‑acting β‑agonists and anticholinergic bronchodilators (e.g., ipratropium) should be administered. Grade A recommendation. 9
If a prompt response is not achieved with the first agent at maximal dose, the other bronchodilator should be added thereafter. Grade A recommendation. 10
Theophylline should not be used during acute exacerbations. Grade D (harm outweighs benefit). 7
Antibiotics are recommended for acute exacerbations, especially in patients with severe exacerbations and more severe baseline airflow obstruction. Grade A recommendation. 8

If cough and bronchospasm remain inadequate after 2 weeks of ipratropium monotherapy, a short‑acting β‑agonist may be added for additional bronchodilation and potential cough relief. Grade A recommendation. 9
For patients with severe airflow obstruction (FEV₁ < 50 % predicted) or frequent exacerbations, a combination of a long‑acting β‑agonist (LABA) and inhaled corticosteroid (ICS) should be considered. Grade A recommendation. 10
LABA/ICS combination therapy reduces exacerbation rates and helps control chronic cough in this population. Grade A recommendation. 8
Theophylline may be considered as an alternative option to control chronic cough, provided careful monitoring for complications; Grade A recommendation. 9

Long‑term prophylactic antibiotics are not recommended for stable chronic bronchitis; evidence shows no benefit. Grade I (insufficient evidence). 9
Oral corticosteroids should not be used for long‑term management of stable chronic bronchitis due to lack of benefit and significant side‑effects. Grade I. 7
Expectorants lack evidence of effectiveness and are not recommended. Grade I. 8
Postural drainage and chest percussion have no proven clinical benefit and should be avoided. Grade I. 10

Smoking cessation is the most effective intervention to improve or eliminate cough in chronic bronchitis; approximately 90 % of patients experience cough resolution after quitting. Grade A recommendation. 9